Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, discusses patient support options for those who switch to biosimilar adalimumab in the United Kingdom.
So patients have access to our helpline. They are able to either email us or call us if they do have a problem once switched. We’ve also, with our local support group, they have helplines that they can call. There’s lots of mechanisms to feed back any queries and to support patients who’ve switched.